Related Experiment Video
Updated: Mar 14, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
NRAS, NRAS, Which Mutation Is Fairest of Them All?
Christine Grill1, Lionel Larue1
1Institut Curie, Paris Sciences et Lettres Research University, Institut National de la Santé et de la Recherche Médicale U1021, Normal and Pathological Development of Melanocytes, Orsay, France; Université Paris-Sud, Université Paris-Saclay, Centre National de la Recherche Scientifique Unité Mixte de Recherche 3347, Orsay, France; Equipe Labellisée Ligue Contre le Cancer, Orsay, France.
Abstract:
In 28% of melanomas, NRAS is mutated in one of two hotspots: G12 or Q61. Phosphoproteomic analysis of primary human melanocytes transduced with G12 and Q61 showed different phosphorylation events in the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Surprisingly, NRAS(G12) modulates the PI3K pathway and overexpresses the kinase PIM2, whereas NRAS(Q61) is associated with the MAPK pathway and overexpression of CK2α.
Insights
Mutations in NRAS, common in melanoma, activate distinct signaling pathways. NRAS G12 impacts the phosphoinositide 3-kinase (PI3K) pathway, while NRAS Q61 affects the mitogen-activated protein kinase (MAPK) pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- NRAS mutations occur in 28% of melanomas, primarily at G12 or Q61 hotspots.
- Understanding NRAS mutation-specific signaling is crucial for targeted melanoma therapies.
Purpose of the Study:
- To investigate the distinct downstream signaling effects of NRAS G12 and Q61 mutations in melanoma.
Main Methods:
- Phosphoproteomic analysis was performed on primary human melanocytes engineered with NRAS G12 and Q61 mutations.
- Comparative analysis of signaling pathway modulation and kinase overexpression.
Main Results:
- NRAS G12 mutation distinctly modulated the phosphoinositide 3-kinase (PI3K) pathway, leading to PIM2 kinase overexpression.
- NRAS Q61 mutation was associated with the mitogen-activated protein kinase (MAPK) pathway and CK2α overexpression.
Conclusions:
- NRAS G12 and Q61 mutations activate divergent signaling cascades in melanoma.
- These findings highlight pathway-specific therapeutic strategies for NRAS-mutated melanomas.
Related Concept Videos
The Ras Gene
Ras is a...
The Ras Gene
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Abnormal Proliferation

